688 articles in this topic
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
A gut metabolite produced after chemo reprograms bone marrow immune cells, creating a lasting shield against colorectal cancer liver metastasis.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
A Nature study reveals lung tumors activate vagal nerves to drive sympathetic signaling that shuts down anti-tumor immunity.
Neuronal signals fuel small cell lung cancer via the vagus nerve and direct neuron-to-tumor synapses, opening new therapeutic targets.
A landmark screen of approved kinase inhibitors reveals 94% of cancer mutations are already targetable — and uncovers surprising new drug uses.
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
A landmark genomic analysis of 50,000 tumors maps cancer-driving mutations across tumor types, revealing critical patterns that could reshape precision oncology.
A 13-year Italian cohort study finds ultra-processed foods don't raise breast cancer risk, but alcoholic beverages do.
Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.
A landmark RET-fusion lung cancer trial shows strong PFS gains but a puzzling OS signal — revealing a critical flaw in how crossover trials are designed.
A pooled analysis of 2.5 million people links higher BMI and waist size to bladder cancer risk — but only in males.
